Gustavo A. Angarita, MD, MHS

Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut; Connecticut Mental Health Center, New Haven, Connecticut; Clinical Neuroscience Research Unit, Connecticut Mental Health Center, New Haven, Connecticut

  • 3Articles
  • 10.4KReads
  • 2008–2026Active
  • 22Collaborators
  • 28Citations

About

Gustavo A. Angarita, MD, MHS, is affiliated with the Department of Psychiatry at Yale University School of Medicine and the Connecticut Mental Health Center in New Haven, Connecticut, including its Clinical Neuroscience Research Unit. His publications in Psychiatrist.com span from 2008 to 2026 and focus on addiction and attention-deficit/hyperactivity disorder, addressing topics such as pharmacotherapies for co-occurring stimulant use disorder and ADHD, psychiatric disorders and crime epidemiology, and clinical trials of long-acting risperidone in cocaine dependence. He has frequently collaborated with co-authors including A. Eden Evins, Alec W. Buchanan, and Alejandra Pulido-Saavedra.

Publications

JCP
Pharmacotherapies for Co-Occurring Stimulant Use Disorder and ADHD
Meta-Analysis

Pharmacotherapies for Co-Occurring Stimulant Use Disorder and ADHD

August 31, 2026

Stimulant-based pharmacotherapies, particularly higher-dose methylphenidate and mixed amphetamine salts, were associated with superior outcomes for both stimulant-use indicators and ADHD symptoms.
, , , et al
JCP
Original Research

Psychiatric Disorders and Crime

February 12, 2019

Although possible connections between mental illness and crime often attract national attention, there are currently no estimates of the relationship between DSM-5 psychiatric disorders and crime among US adults....
, , , et al
JCP
Article

A Randomized, Double-Blind, Placebo-Controlled Trial of Long-Acting Risperidone in Cocaine-Dependent Men

March 14, 2008

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe